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CLINICAL SNIPPETS
Polymorphism 
Predictors
Previous studies have reported 
associations between single-
nucleotide polymorphisms 
(SNPs) in the tumor necrosis 
factor (TNF)-α gene and 
psoriatic arthritis (PsA). In 
a study of 57 PsA patients 
and 155 controls, Murdaca 
and colleagues discovered 
that SNP +489 variant A was 
strongly associated with PsA 
susceptibility and clinical 
severity. Interestingly, at this 
position the G allele was 
associated with increased 
response to the TNF-α inhibitor 
etanercept, whereas the A 
allele favored the response to 
adalimumab. These results may 
pave the way for prediction of 
a patient’s clinical response to 
specific TNF-α inhibitors.  
See page 2503 
IMQ Affects 
Pleiotropic Pathways
In a melanoma-bearing 
humanized mouse model, 
Aspord and colleagues 
demonstrated that imiquimod 
(IMQ) effectively combats 
melanoma via mobilization 
and activation of plasmacytoid 
dendritic cells, triggering 
their cytotoxic functions. 
Surprisingly, IMQ inhibited 
tumor vascularization in vivo. 
To date, only case reports have 
demonstrated success with 
this synthetic Toll-like receptor 
ligand against melanoma, 
and the drug has not been 
approved for clinical use for 
melanoma because of a lack of 
understanding of its mode of 
action. These findings will clearly 
influence the use of IMQ as a 
treatment against metastatic 
melanoma. See page 2551
In the Mut-Driver’s Seat
Using exome-
level sequencing 
in combination 
with target exon 
sequencing of 
more than 170 
cutaneous squamous cell carcinomas (cSCCs) and squamoproliferative lesions that 
commonly arise in patients receiving the systemic kinase inhibitor vemurafenib, South 
and colleagues found that cSCCs have a massive mutation burden that exceeds nearly 
every common cancer with metastatic potential. NOTCH receptors, which have previ-
ously been identified as Mut-driver genes in sporadic cSCC, were significantly mutated 
in these cSCCs, and such mutation appears to be an early event in squamous cell 
carcinogenesis. Together with previous results, these findings suggest that NOTCH1 
acts as a tumor suppressor for HRAS-driven skin carcinogenesis. See page 2630 
EGFR Diversity
Aberrant EGFR signaling has been implicated in 
inflammatory and malignant diseases. Whereas 
gain-of-function mutations in EGFR are typical in 
tumors, loss-of-function mutations have not been 
previously reported. Campbell and colleagues 
uncovered a homozygous EGFR missense mutation 
(c.1283 G>A) in a patient with lifelong inflamma-
tion of the skin, bowels, and lungs. This mutant 
EGFR was highly unstable at the plasma membrane, 
was more susceptible to constitutive endocytosis, 
and disrupted downstream Akt and ERK signal-
ing. Consistent with a loss of functional EGFR, this 
patient exhibited clinical characteristics similar to 
side effects of EGFR inhibitors and to mouse models 
of EGFR impairment. See page 2570 
As and Bs
UVA1 constitutes the majority of artificial tan-
ning sources and solar UV radiation, which 
has been linked to photoaging and photocar-
cinogenesis. Tewari and colleagues examined 
the biological effects of spectrally pure UVB 
and UVA1 and found that both sources pref-
erentially upregulated extracellular matrix 
remodeling genes. UVA1 preferentially induced 
matrix metalloproteinase 12 (MMP12), whereas 
UVB induced MMP1, MMP3, and MMP10. 
Upregulation of MMP12 gene expression resulted in increased levels of the MMP12 
protein elastase. The investigators speculate that upregulation of this elastase contrib-
utes to loss of skin elasticity—a hallmark of photoaging—suggesting that inhibition 
of MMP12 may be a useful strategy for protection against photoaging. See page 2598
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